| Name | Title | Contact Details |
|---|---|---|
Maureen Carroll |
Senior Director, Strategic Talent Programs | Profile |
Brian Jochim |
Head, Global Talent Acquisition | Profile |
Matthew Sarantopoulos |
Director of Global Tax Accounting | Profile |
Matt Block |
Senior Vice President, Finance | Profile |
James Mock |
CFO | Profile |
Sengenics is a functional proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX™ was invented and patented by Professor Jonathan Blackburn whilst he was a member of the faculty at the University of Cambridge. Jonathan is the CSO of Sengenics. The key application of KREX™ is the discovery of autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX™ can also be used to identify autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions years before conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.
Transforming medicine through cellular therapies that restore, regenerate, and repair tissues and organs
Vital Pharma Inc. is a West Palm Beach, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases. Our founders` groundbreaking discoveries in RNA interference offer a powerful therapeutic approach to halt diseases at their source.
BlossomHill Therapeutics is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.